drugset / Trial / NCT06487000
Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the efficacy and safety of oral administration of dose-dependent EC-18 for 16 weeks in patients with moderate to severe atopic dermatitis
Timeline
- Start
- 2025-05
- Primary completion
- 2026-10
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MOSEDIPIMOD | Small molecule | 1000 mg | Oral |
| Subject | MOSEDIPIMOD | Small molecule | 2000 mg | Oral |